In particular, GOBO-based analysis (http://co.bmc.lu.se/gobo/gobo.pl) [50] indicates that TLK2 is upregulated in 37 % luminal (estrogen receptor (ER)-positive) breast tumours with grade 3-stratified multivariate analysis showing a hazard ratio of 2.25 (p = 10−5) and poor survival (p < 0.01) in these tumours (Additional file 1). Here, ESR1 is linked to breast neoplasm.